Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: clinical features, risk factors, and posaconazole profiles.
Sign Up to like & getrecommendations! Published in 2023 at "Medical mycology"
DOI: 10.1093/mmy/myad046
Abstract: Posaconazole (PSC) delayed-release tablet prophylaxis is the standard of care for preventing invasive fungal infection (IFI) in patients with acute myeloid leukemia undergoing myelosuppressive chemotherapy. The clinical features, risk factors, and PSC profiles of breakthrough… read more here.
Keywords: tablet prophylaxis; risk factors; myeloid malignancy; patients myeloid ... See more keywords